Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents

被引：38

作者：

Czarniecki, Marcin ^{[1
]}

Mena, Esther ^{[1
]}

Lindenberg, Liza ^{[1
]}

Cacko, Marek ^{[2
]}

Harmon, Stephanie ^{[1
,3
]}

Radtke, Jan Philipp ^{[4
]}

Giesel, Frederick ^{[5
]}

Turkbey, Baris ^{[1
]}

Choyke, Peter L. ^{[1
]}

机构：

[1] NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA

[2] Med Univ Warsaw, Dept Nucl Med, Warsaw, Poland

[3] NCI, Clin Res Directorate, Clin Monitoring Res Program, Frederick Natl Lab Canc Res, Frederick, MD 21701 USA

[4] Heidelberg Univ Hosp, Dept Urol, INF 400, D-69120 Heidelberg, Germany

[5] Heidelberg Univ Hosp, Dept Nucl Med, INF 400, D-69120 Heidelberg, Germany

来源：

TRANSLATIONAL ANDROLOGY AND UROLOGY | 2018年 / 7卷 / 05期

基金：

美国国家卫生研究院;

关键词：

Positron emission tomography/computed tomography (PET/CT); nuclear medicine; prostatic neoplasms; tomography; emission-computed; single-photon; gallium; I-AND-T; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; RADIOLIGAND THERAPY; RADIATION-DOSIMETRY; CANCER PATIENTS; TUMOR LESIONS; F-18-DCFBC PET/CT; HBED-CC; BIODISTRIBUTION;

D O I：

10.21037/tau.2018.08.03

中图分类号：

R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

摘要：

Prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) is an emerging prostate cancer imaging method, which has been reported to have a higher sensitivity and specificity than the currently approved PET imaging agents. Multiple PSMA ligands are being investigated around the world and applications range from primary tumor characterization, to local staging, biochemical recurrence, metastasis, and image-guided interventions. The most investigated PET tracers are labelled with 68-Gallium or 18-Fluoride and are discussed in this review. Additionally, Tc-99m labeled PSMA agents for single photon emission computed tomography (SPECT) imaging are elucidated as an alternative method of PSMA image acquisition.

引用

页码：831 / 843

页数：13

共 70 条

[1] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].

Afshar-Oromieh, A. ;

Malcher, A. ;

Eder, M. ;

Eisenhut, M. ;

Linhart, H. G. ;

Hadaschik, B. A. ;

Holland-Letz, T. ;

Giesel, F. L. ;

Kratochwil, C. ;

Haufe, S. ;

Haberkorn, U. ;

Zechmann, C. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495

[2] The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].

Afshar-Oromieh, Ali ;

Hetzheim, Henrik ;

Kratochwil, Clemens ;

Benesova, Martina ;

Eder, Matthias ;

Neels, Oliver C. ;

Eisenhut, Michael ;

Kuebler, Wolfgang ;

Holland-Letz, Tim ;

Giesel, Frederik L. ;

Mier, Walter ;

Kopka, Klaus ;

Haberkorn, Uwe .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705

[3] The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer [J].

Afshar-Oromieh, Ali ;

Avtzi, Eleni ;

Giesel, Frederik L. ;

Holland-Letz, Tim ;

Linhart, Heinz G. ;

Eder, Matthias ;

Eisenhut, Michael ;

Boxler, Silvan ;

Hadaschik, Boris A. ;

Kratochwil, Clemens ;

Weichert, Wilko ;

Kopka, Klaus ;

Debus, Juergen ;

Haberkorn, Uwe .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :197-209

[4] Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer [J].

Afshar-Oromieh, Ali ;

Zechmann, Christian M. ;

Malcher, Anna ;

Eder, Matthias ;

Eisenhut, Michael ;

Linhart, Heinz G. ;

Holland-Letz, Tim ;

Hadaschik, Boris A. ;

Giesel, Frederik L. ;

Debus, Juergen ;

Haberkorn, Uwe .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (01) :11-20

[5] Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study [J].

Ahmadzadehfar, Hojjat ;

Rahbar, Kambiz ;

Kuerpig, Stefan ;

Boegemann, Martin ;

Claesener, Michael ;

Eppard, Elisabeth ;

Gaertner, Florian ;

Rogenhofer, Sebastian ;

Schaefers, Michael ;

Essler, Markus .

EJNMMI RESEARCH, 2015, 5 :1-8

[6] 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].

Baum, Richard P. ;

Kulkarni, Harshad R. ;

Schuchardt, Christiane ;

Singh, Aviral ;

Wirtz, Martina ;

Wiessalla, Stefan ;

Schottelius, Margret ;

Mueller, Dirk ;

Klette, Ingo ;

Wester, Hans-Juergen .

JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013

[7]

Bauman G., 2016, European Urology Focus

[8] Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].

Benesova, Martina ;

Schaefer, Martin ;

Bauder-Wuest, Ulrike ;

Afshar-Oromieh, Ali ;

Kratochwil, Clemens ;

Mier, Walter ;

Haberkorn, Uwe ;

Kopka, Klaus ;

Eder, Matthias .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920

[9] Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC [J].

Berliner, Christoph ;

Tienken, Milena ;

Frenzel, Thorsten ;

Kobayashi, Yuske ;

Helberg, Annabelle ;

Kirchner, Uve ;

Klutmann, Susanne ;

Beyersdorff, Dirk ;

Budaeus, Lars ;

Wester, Hans-Juergen ;

Mester, Janos ;

Bannas, Peter .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (04) :670-677

[10] Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy [J].

Budaeus, Lars ;

Leyh-Bannurah, Sami-Ramzi ;

Salomon, Georg ;

Michl, Uwe ;

Heinzer, Hans ;

Huland, Hartwig ;

Graefen, Markus ;

Steuber, Thomas ;

Rosenbaum, Clemens .

EUROPEAN UROLOGY, 2016, 69 (03) :393-396

← 1 2 3 4 5 6 7 →